Inappropriate Elevation of Serum Thyrotropin Levels in Patients Treated with Axitinib
Authors:
- 1 April 2013
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 23 (4) , 443-448
Abstract
Background: Although anticancer treatment with the tyrosine kinase inhibitor (TKI) axitinib frequently causes thyroid dysfunction, the associated mechanism and clinical features have not been elucidated. Methods: Six patients were treated with axitinib for metastatic renal cell carcinoma at the Hamamatsu University School of Medicine between 2008 and 2010. We reviewed their thyroid function results and compared them to those of patients treated with two other TKIs, sunitinib or sorafenib, and to those of subjects with normal hypothalamic–pituitary–thyroid (HPT) function. Results: Axitinib-induced thyroid dysfunction was observed in all patients, and two patterns were observed: increased serum thyrotropin (TSH) levels within one month after administration occurred in five patients and transient thyrotoxicosis due to destructive thyroiditis occurred in five patients within 7 months of treatment. Four patients exhibited both. When the relationship between the serum TSH and thyroid hormones was evaluated using plots of TSH versus both free thyroxine and free triiodothyronine, four patients showed an inappropriate elevation of serum TSH during administration of axitinib. Their values apparently shifted against the regression line compared to data from patients with a normal HPT function. A similar tendency, though weaker, was observed in some patients treated with sunitinib or sorafenib. Conclusion: This is the first study to report an inappropriate elevation of serum TSH levels in patients treated with axitinib.Keywords
This publication has 20 references indexed in Scilit:
- Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell CarcinomaJapanese Journal of Clinical Oncology, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell CarcinomaEuropean Journal of Cancer, 2011
- Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current StatusCurrent Oncology Reports, 2011
- Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patientsInvestigational New Drugs, 2011
- Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid LeukemiaThyroid®, 2010
- Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 DeiodinationThe Journal of Clinical Endocrinology & Metabolism, 2010
- Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinomaEndocrine Journal, 2010
- Effect of axitinib (AG‐013736) on fatigue, thyroid‐stimulating hormone, and biomarkers: A phase I study in Japanese patientsCancer Science, 2009
- Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxineAnnals of Oncology, 2006